JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $165

Benzinga · 1d ago
JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $165.